Document is current

Article History

Received: 24 February 2022

Accepted: 17 May 2022

First Online: 7 June 2022

Declarations

:

: Toshirou Nishida reports Honoraria from Pfizer and Otsuka outside the submitted work. Masato Ozaka reports Honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Pfizer, Novartis, Bayer, Yakult Co. Ltd., Eisai Co., EA Pharma Co., MSD, and AstraZeneka K.K. outside the submitted work. Yoshito Komatsu reports Speakers’ bureau from Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, and Bayer, and Research fundings from Ono Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Chugai Pharmaceutical, and IQVIA outside the submitted work. Yukinori Kurokawa reports Research fundings from Taiho Pharmaceutical, Ono Pharmaceutical, and MSD, and Lecture fees from Taiho Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Yakult Honsha, Nippon Kayaku, Bristol-Myers Squibb, Takeda Pharmaceutical, and Daiichi Sankyo outside the submitted work. Yuko Kitagawa reports Honoraria from Asahi Kasei Pharma, Taiho Pharmaceutical, Chugai Pharmaceutical, Otsuka Pharmaceutical Factory Inc., Ono Pharmaceutical, Kaken Pharmaceutical Co., AstraZeneka K.K., Ethicon Inc., Olympus Co., Nippon Covidien Inc., Bristol-Myers Squibb, MSD, and Smith & Nephew K.K., and Research fundings from Chugai Pharmaceutical, Taiho Pharmaceutical, Yakult Co. Ltd., Otsuka Pharmaceutical Co., Takeda Pharmaceutical, Ono Pharmaceutical, Tsumura Co., Kyowa Hakkou Kirin Co., EA Pharma Co., Medicon Inc., Kaken Pharmaceutical Co., Eizai Co., Otsuka Pharmaceutical Factory Inc., Teijin Pharma, Nihon Pharmaceutical Co., and Nippon Covidien Inc., and Role of consulting/advisory from Bristol-Myers Squibb, and Ono Pharmaceutical outside the submitted work. No disclosures are reported from the other authors.

: Ethical approval was initially obtained from the institutional review board (IRB) of the National Cancer Center (No. 2012–264) and then from the IRBs of the other participating hospitals. Written informed consent was obtained from all participating patients. This trial is registered with the UMIN Clinical Trials Registry, number UMIN000009531.

: All authors have confirmed the final version of the submitted manuscript and have approved.

Free to read: This content has been made available to all.